US2017196839A1PendingUtilityA1
Neurodegenerative diseases and methods of modeling
Est. expiryNov 26, 2028(~2.3 yrs left)· nominal 20-yr term from priority
A61K 31/4164A61K 31/403A61P 25/00A61K 31/4166A61K 31/40A61K 31/7052Y02A50/30
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to methods for neuroprotection, promoting survival of motor neurons and the treatment of motor neuron diseases by preventing cell signaling through the classic prostaglandin D2 receptor DP1.
Claims
exact text as granted — not AI-modified1 - 19 . (canceled)
20 . A method of treating a subject with a motor neuron disease, the method comprising administering to a subject in need thereof an inhibitor of a prostaglandin D2 DP1 receptor.
21 . The method of claim 20 , wherein the inhibitor of a prostaglandin D2 DP1 receptor is selected from the group consisting of: a small molecule, a nucleic acid molecule, a protein and combinations thereof.
22 . The method of claim 20 , wherein the inhibitor of a prostaglandin D2 DP1 receptor is a small molecule.
23 . The method of claim 20 , wherein the inhibitor of the prostaglandin D2 DP1 receptor comprises the compound of formula (I):
wherein: R 1 is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which can be optionally substituted; R 2 is H, halo, alkyl, alkenyl or alkynyl, each of which can be optionally substituted; R 3 is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which can be optionally substituted; and X is NH, C(O) or CH 2 .
24 . The method of claim 23 , wherein the inhibitor of the prostaglandin D2 DP1 receptor is the compound:
25 . The method of claim 20 , wherein the inhibitor of the prostaglandin D2 DP1 receptor is the compound:
26 . The method of claim 20 , wherein the motor neuron disease is selected from a group consisting of amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), pseudobulbar palsy, progressive bulbar palsy, spinal muscular atrophy (SMA) and post-polio syndrome.
27 . The method of claim 20 , wherein the motor neuron disease is amyotrophic lateral sclerosis (ALS).
28 . The method of claim 20 , wherein the motor neuron disease is spinal muscular atrophy (SMA).
29 . The method of claim 20 , wherein the motor neuron disease is associated with a SOD1 mutation in at least one allele.
30 . The method of claim 20 , wherein the inhibitor of the prostaglandin D2 DP1 receptor counteract the toxic affects of a glial cell carrying a SOD1 mutation in at least one allele.
31 . The method of claim 20 , wherein the inhibitor of the prostaglandin D2 DP1 receptor inhibits cell death caused by glial cells carrying a SOD1 mutation in at least one allele.
32 . The method of claim 20 , wherein the inhibitor of the prostaglandin D2 DP1 receptor rescues motor neuron loss.
33 . The method of claim 20 , wherein the subject is a mammal.
34 . The method of claim 20 , wherein the subject is a human.
35 . A method of treating a subject with a motor neuron disease associated with a SOD1 mutation in at least one allele, the method comprising administering to a subject in need thereof an inhibitor of a prostaglandin D2 DP1 receptor and thereby treating the motor neuron disease, wherein the inhibitor of the prostaglandin D2 DP1 receptor is the compound:
36 . The method of claim 35 , wherein the motor neuron disease is wherein the motor neuron disease is amyotrophic lateral sclerosis.
37 . The method of claim 35 , wherein the inhibitor of the prostaglandin D2 DP1 receptor inhibits cell death caused by glial cells carrying a SOD1 mutation in at least one allele.
38 . The method of claim 35 , wherein the inhibitor of the prostaglandin D2 DP1 receptor rescues motor neuron loss.
39 . The method of claim 35 , wherein the subject is a human.Join the waitlist — get patent alerts
Track US2017196839A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.